IQVIA Holdings Inc. $IQV Stock: Lido Advisors LLC Increases Position

Lido Advisors LLC lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 106.6% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,145 shares of the medical research company’s stock after buying an additional 4,718 shares during the period. Lido Advisors LLC’s holdings in IQVIA were worth $2,459,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the business. Keybank National Association OH boosted its position in IQVIA by 7.1% in the third quarter. Keybank National Association OH now owns 10,239 shares of the medical research company’s stock worth $2,753,000 after purchasing an additional 681 shares during the last quarter. 71 West Capital Partners increased its position in shares of IQVIA by 57.2% during the 3rd quarter. 71 West Capital Partners now owns 2,083 shares of the medical research company’s stock valued at $560,000 after purchasing an additional 758 shares during the last quarter. Pinion Investment Advisors LLC purchased a new stake in shares of IQVIA during the 3rd quarter valued at $226,000. AlphaCore Capital LLC increased its position in shares of IQVIA by 42.1% during the 3rd quarter. AlphaCore Capital LLC now owns 1,979 shares of the medical research company’s stock valued at $532,000 after purchasing an additional 586 shares during the last quarter. Finally, Running Oak Capital LLC raised its stake in shares of IQVIA by 1.6% during the 3rd quarter. Running Oak Capital LLC now owns 59,587 shares of the medical research company’s stock worth $16,020,000 after purchasing an additional 914 shares during the period. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on IQV. Robert W. Baird boosted their price target on shares of IQVIA from $324.00 to $328.00 and gave the stock an “outperform” rating in a report on Tuesday, October 27th. Leerink Partners increased their price target on shares of IQVIA from $280.00 to $310.00 and gave the company an “outperform” rating in a research report on Thursday, October 8th. TD Cowen raised their price objective on shares of IQVIA from $288.00 to $307.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Royal Bank Of Canada lifted their price objective on shares of IQVIA from $247.00 to $319.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Finally, Deutsche Bank dropped their target price on shares of IQVIA from $191.00 to $179.00 in a research note on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $294.21.

IQVIA Stock Performance

NYSE IQV traded down $5.67 on Friday, hitting $265.44. 1,986,072 shares of the stock traded hands, compared to its average volume of 1,407,100. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.83 and a current ratio of 0.83. The business’s fifty day moving average is $267.55 and its two-hundred day moving average is $211.88. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $284.50. The firm has a market capitalization of $43.74 billion, a price-to-earnings ratio of 32.25, a PEG ratio of 2.41 and a beta of 1.16.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.26 by $0.08. The firm had revenue of $4.43 billion for the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. The business’s revenue was up 8.0% on a year-over-year basis. During the same period in the previous year, the company posted $3.00 earnings per share. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 4,446 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $278.83, for a total value of $1,239,678.18. Following the sale, the insider directly owned 24,989 shares in the company, valued at approximately $6,967,682.87. The trade was a 15.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider James G. Berkshire sold 2,668 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total transaction of $697,228.44. Following the sale, the insider directly owned 10,890 shares in the company, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.